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Abstract
Objectives: Different thermotherapeutic modalities such as transurethral microwave therapy or
transurethral needle ablation have been developed to provide effective alternatives to surgical
management of benign prostate hyperplasia (BPH). The mechanisms of thermotherapy, how-
ever, are not completely understood. We developed a model to investigate the effects of heat
application on stromal cell viability and contractility.
Methods: Cells isolated from prostatectomy and cystoprostatectomy specimens were cultured
in a selective medium. Temperatures ranging from 37 to 50°C were applied for 1 h. Cell con-
traction was visualized by means of a cell culture microscope equipped with a time-lapse video
system. For quantitative analysis, the percentage of contracting cells was evaluated; 10 íM of
phenylephrine were applied for adrenergic stimulation of the cells.
Results: On immunohistochemistry and phase-contrast microscopy, these cells were identified
as prostatic myofibroblasts. Incubation at 50°C for 1 h in vitro induced immediate death of all
cells, whereas at 45°C all cells survived. At 37°C 55% of the cells were seen to contract after ad-
dition of phenylephrine. Immediately after incubation at 45°C contraction rate decreased to
29%, but returned to 46% 1 day later.
Conclusions: With this model, it is possible to study the mechanisms of thermotherapy in vitro.
The results suggest that the effects of thermotherapy are due to the induction of cell death
rather than to reduced stromal cell contractility. Furthermore, the data show that treatment is
probably only successful if temperatures in excess of 50°C are maintained.
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Introduction
BPH is one of the commonest diseases in elderly men. In
BPH, urethral obstruction results from a static component
(i.e. enlargement of the prostate) as well as a dynamic
mechanism (i.e. increased contractility of prostatic smooth
muscle cells). Various therapeutic modalities have been de-
veloped to counteract these two phenomena. Volume reduc-
tion can be achieved by surgical procedures such as
transurethral resection of the prostate, whereas smooth
muscle cell contractility is reduced by Æ1-adrenoceptor an-
tagonists.
More recently, various modalities of thermal therapy,
e.g. transurethral microwave therapy (TUMT), transure-
thral needle ablation (TUNA) and others, have been intro-
duced for the treatment of bladder outlet obstruction sec-
ondary to benign prostate hyperplasia (BPH) [1–3]. The
mechanisms of thermotherapy, however, are still not entire-
ly understood. Clinical studies have demonstrated that mi-
crowave therapy, for example, does not significantly reduce
the size of the prostate in BPH patients [4]. Hence, it was
assumed that thermotherapy acts by reducing prostatic
smooth muscle cell contractility [5]. The aim of the present
study was to develop a model for investigating prostatic
stromal cell contractility and viability after heat application.
Material and Methods
Cells were isolated from human prostatic tissue obtained from 10
prostatectomy and cystoprostatectomy specimens of BPH, prostate
cancer and bladder cancer patients. The prostates were dissected by a
standardized technique, and tissue was taken from the periurethral
zone. Specimens from cancer patients were examined histologically
by frozen section to exclude tumor invasion of the tissue from which
the cells were taken. Only small samples were taken so as not to in-
terfere with tumor staging and grading by the pathologist. Because of
the small amount of tissue available, the explant culture technique was
used. The tissue was cut into small pieces which were subsequently
attached to the bottom of a cell culture flask (Falcon). Then, the cul-
ture medium was added, which consisted of modified MCDB-131
with 15% dialyzed horse serum, 10 mM of HEPES, pH 7.2, 2% peni-
cillin-streptomycin solution and 2% MEM-EAGLE nonessential
amino acids. Furthermore, 5 íg/ml of insulin, 10 íg/ml of transferrin
(Boehringer, Mannheim, Germany), 5 ng/ml of sodium-selenite,
0.1 íM of estradiol and 0.1 íM of dexamethasone (Sigma Chemical
Company, St. Louis, Mo., USA) were added. This culture medium
was previously shown to stimulate the growth of smooth muscle cells
and to suppress the growth of fibroblasts [6]. The cells were incubat-
ed at 37°C in 5% CO2 and 95% humidity. The first cell passage with
trypsin/EDTA was performed once approximately 50% of the bottom
of the culture flask were covered with cells. Further passages were
done at intervals of 5–10 days depending on the growth rate. Im-
munohistochemical staining was performed to characterize the cells.
Antibodies to smooth muscle cell a-actin, myosin, desmin and vi-
mentin (Sigma) as well as an antifibroblast antibody (Dianova, Ham-
burg, Germany) were used. The procedure has been described in pre-
vious publications [7]. A prostatic carcinoma cell line (LNCaP) and
genital skin fibroblasts served as controls.
For video microscopy, the bottom of the culture flasks was coated
with the viscous agent Cell-tak (Collaborative Biomedical Products,
Bedford, Mass., USA) in a concentration of 4 íg/cm2. Observation
was performed with a cell culture microscope at E200 magnification.
A videosequence was performed from a previously selected field
within the cell layer in each particular experiment by means of a vide-
orecorder connected to the microscope. Because of the low velocity of
cell contractions, a time-lapse video system was mandatory. With this
system, an observation of cell contractions in sequences representing
approximately 1 s real time per frame was possible. A number of
12–25 (mean 16) cells were observed within each microscopic field
under investigation. Constant physiological conditions were main-
tained throughout the experiment by an incubation chamber around
the microscope. The temperature could be set between 20 and 55°C.
In heat exposure experiments, the chamber was heated to tempera-
tures of 45 or 50°C. The cell culture flask was placed into the cham-
ber before starting video observation. Heat exposure at a constant
temperature was continued for 60 min. Following heat exposure, all
cells in the culture flask were investigated morphologically. Video
monitoring was continued as long as there were viable cells. Experi-
ments in which all cells became necrotic were stopped. The tempera-
ture was downregulated to 37°C after 1 h of heat exposure. Then the
adrenergic contraction stimulant phenylephrine was added to the cul-
ture flask. The agent was dissolved in culture medium to obtain an end
concentration of 10 íM. In this concentration, phenylephrine has pre-
viously been shown to effectively induce stromal cell contractions [7].
Phenylephrine was added to the culture medium immediately after
heat exposure, and the cells were observed for another 2 h. Control
experiments with cultures from the same cell strain were performed
prior to heat exposure studies. In control experiments, the cells were
incubated at 37°C throughout the experiment. After an initial 60-min
observation period, 10 íM of phenylephrine were added and video
microscopy continued for another 2 h. In sham experiments, cells
were observed for 3 h at 37°C using a culture medium containing no
stimulants.
For quantitative analysis, the total number cells in the observation
field as well as the number of contracting cells were evaluated. Re-
sults are presented as percentage of contracting cells. For statistical
analysis, the Kruskal-Wallis test (Abacus Concepts, Berkeley, Calif.,
USA) was used. Data are presented as mean values with standard de-
viations.
Results
With this culture model, a first cell passage was per-
formed after 2 weeks. After 2–3 passages, only cells with
stromal morphology were found to be present in the culture.
The experiments were initiated after the 3rd or 4th passage,
when the cells exhibited sufficient contractility. Seven to
9 passages could be performed successfully in most cell
strains. Immunohistochemical staining was positive for
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smooth muscle cell Æ-actin, myosin and desmin. However,
a weak positive staining was also observed for the antifi-
broblast antibody, thus identifying these cells as myofibro-
blasts, an intermediate form between smooth muscle cells
and fibroblasts. Genital skin fibroblasts were negative for
the muscle cell markers, but positive for the antifibroblast
antibody, whereas LNCaP cells were negative for all
smooth muscle cell markers. Immunohistochemical docu-
mentation has been presented in previous publications [6,
7].
Morphologically, the cells remained unchanged after in-
cubation at 37 and 45°C for 1 h. No cell death was de-
tectable by means of video microscopy. The cells also re-
mained viable the following days after heat exposure, and
further cell passages could be performed successfully. If in-
cubated at 50°C, however, all cells began to shrink after
30 min, and by the end of the experiment only condensed
spots of the cells were left (fig. 1). No further cell passages
could be performed since the cells did not recover any
more.
Under the experimental conditions described, cell con-
tractions could be well documented by video microscopy
(fig. 2). Contractions were seen as shortenings of the cells
and could be clearly distinguished from other cell move-
ments like pseudopadal extension, which were also recog-
nized during video observation. Contractions were seen un-
til the 5th day after cell passage; they were slow and could
therefore be observed with the help of the time-lapse system
only. There was a great variability in contractility between
different cell strains. Only cell strains with a contraction
rate of at least 25% after adrenergic stimulation in control
experiments were used for the present study. At 37°C, 18%
of unstimulated cells were seen to contract during the 2-
hour observation period (fig. 3). After addition of 10 íM of
phenylephrine, the contraction rate increased significantly
(55%). The first contractions were noted 5–30 min after the
application of the agent. The observation period was not
prolonged more than 2 h because at that point of time, the
contraction rate began to decrease slowly. At 45°C, cell
contractility was found to decrease significantly (29%).
However, this was only a transient effect which was ob-
served in the initial phase after heat exposure. Twenty-four
hours after heat application, the contraction rate returned to
46% and remained unchanged after further cell passages. In
none of the experiments was acontractility observed in vi-
able cells at temperatures lower than 50°C. Cells irre-
versibly damaged following incubation at 50°C for 1 h did
not exhibit any contractility upon stimulation with phenyle-
phrine. Genital skin fibroblasts and LNCaP cells showed
pseudopadal extension, but no contractions at all.
Discussion
The stromal compartment, i.e. smooth muscle cells, fi-
broblasts and connective tissue, constitutes a major compo-
nent of the prostate. Morphometric analysis demonstrates
that BPH is primarily a disease of the stromal tissue [8]. In
BPH, bladder outlet obstruction results from two different
mechanisms, first a static component, i.e. an enlargement of
the prostate, and second a dynamic one, resulting from the
increased contractility of prostatic smooth muscle cells.
Prostatic smooth muscle tone is known to be mediated pri-
marily by Æ1-adrenergic stimulation. Various models of pro-
static stromal cell cultures have been described. The culture
model of the present study was described previously [6, 7].
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Fig. 1. Effect of thermotherapy on viability of prostatic stromal cells
as demonstrated by means of videomicroscopy. At 50°C all cells be-
came necrotic within 60 min. a Start of videomicroscopy. b Sixty
minutes after heat exposure.
a
b
Immunohistochemical analysis suggests that the cultured
cells are myofibroblasts, an intermediate form between
smooth muscle cells and fibroblasts. These cells are known
to differentiate into either smooth muscle cells or fibro-
blasts and to possess contractile properties [9]. Complete
differentiation into smooth muscle cells was probably not
possible within a period of 3 days after cell passage. Previ-
ous studies have shown that it takes these cells at least 4–6
days to express highly specific muscle cell markers such as
the smooth muscle myosin heavy chain. However, it was
not possible to prolong the interval between cell passage
and experiment, otherwise the cells would have become too
firmly attached to the culture flask and thus would have
been unable to contract. A major aim of the present study
was to develop a model of prostatic stromal cell contrac-
tions for video microscopy. In a previous study, this model
was successfully used to investigate the effect of Æ1-adreno-
ceptor agonists and antagonists [7]. Phenylephrine was
shown to be a potent stimulant of prostatic stromal cell con-
traction. In the present study, 10 íM of phenylephrine was
applied, because this concentration proved to be most effec-
tive, leading to a contraction rate of 55%.
The effect of thermotherapeutic modalities such as
TUMT or TUNA is still not completely understood. Clinical
studies have shown that microwave therapy for example
does not act primarily by reducing the volume of the
prostate [4, 10]. Histologic investigations have demonstrat-
ed that TUMT induces necrosis of prostatic cells [4, 11–13].
These authors describe uniform hemorrhagic necrosis, tis-
sue devitalization and periurethral thrombosis without sig-
nificant inflammation. It has also been suggested that ther-
motherapy causes a reduction in prostatic smooth muscle
cell contractility or a long-term Æ-blockade [14, 15]. As was
observed in Æ1-adrenoceptor antagonist treatment, reduced
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Fig. 2. By means of videomicroscopy cell
contractions could be documented. The video
sequence demonstrates contraction of the cell
marked by arrows.
Fig. 3. Effect of thermotherapy on contraction rate of prostatic stro-
mal cells. The histogram presents mean values and SD of 23 indepen-
dent experiments with 10 cell strains. *pd0.05 versus 37°C pheny-
lephrine.
smooth muscle cell contractility may improve the symp-
toms of bladder outlet obstruction. There is yet another hy-
pothesis suggesting involvement of neural elements [15,
16]. Histological studies showed severe thermal damage to
intraprostatic nerve fibers caused by TUNA. Denervation of
sympathetic and sensory nerves could explain the clinical
improvement observed after thermotherapy.
In the present study, we have investigated the effects of
heat exposure on the viability and contractility of prostatic
stromal cells. Temperature mapping studies have shown
that high-energy thermotherapies induce temperatures of
45–80°C in the prostatic tissue [17–19]. For our study tem-
peratures of 45 and 50°C were chosen; this corresponds to
the temperatures used in microwave therapy. At 50°C, all
cells instantly became necrotic. Therefore, temperatures
higher than 50°C were not applied in this study. Histologic
examination of human prostatic tissue subjected to mi-
crowave therapy demonstrated that smooth muscle cells are
more sensitive to elevations of temperature than other pro-
static tissues (e.g. glandular cells) [4, 20]. Clinical data have
shown a positive correlation between the stromal-epithelial
cell ratio and the outcome of thermotherapy [21]. Conse-
quently, prostates with a higher stromal cell content show a
better response to thermotherapy. In control experiments,
we were able to show that genital skin fibroblasts have a
higher resistance to heat exposure than prostatic myofibrob-
lasts. At a temperature of 50°C about 30% of the fibroblasts
survived 1 h. This possibly indicates that prostatic smooth
muscle cells are less resistant to heat than other cellular
components of the prostate such as fibroblasts and epithelial
cells. The latter are likely to survive heat exposure and re-
place the necrotic smooth muscle cells. Hence, prostatic
contractility appears to decrease without a reduction in pro-
static volume, thus leading to an improvement in bladder
outlet obstruction. This is in line with histopathologic find-
ings in prostates following thermotherapy, which revealed
infiltration of stromal fibroblasts into the area of necrosis
leading to tissue revitalization [17].
At temperatures of 45°C and less all cells survived.
These findings correspond with results of animal and clin-
ical studies, which yielded a temperature threshold of
45.7°C for the induction of tissue necrosis [4, 17]. Success-
ful cell passages following heat exposure suggest that no
delayed cell damage was induced. At 45°C, the contraction
rate decreased only for a short period of time following heat
application, but increased to nearly previous levels within
24 h. Further cell passages showed unchanged cell contrac-
tility. This clearly demonstrates that heat application has on-
ly a limited effect on the contractility of surviving smooth
muscle cells. Furthermore, the results indicate that a tem-
perature of 45°C can hardly be expected to be effective in
the treatment of BPH. These findings are in line with the re-
sults of clinical studies which did not yield any therapeutic
effects of hyperthermia using temperatures of 42–43°C
[22]. However, it remains to be seen whether the findings of
the present in vitro study actually reflect the in vivo situa-
tion. It may be speculated that cells in a three-dimensional
organ are less sensitive to elevations of temperature than
two-dimensional cell layer. Tissue impedance and tissue
perfusion for example might protect the cells from damage
by heat exposure, reducing effects of thermotherapies in vi-
vo. Under in vivo conditions, thermotherapies might induce
apoptotic rather than necrotic changes in some smooth mus-
cle cells leading to delayed cell death. This could explain
delayed improvement in lower urinary tract symptoms after
microwave therapy, which is accelerated by neoadjuvant
and adjuvant Æ-blockade [23]. Furthermore, heat applica-
tion by TUMT or TUNA might provide additional specific
effects as compared to heating in an incubation chamber.
Conclusions
With the help of video microscopy, it is possible to per-
form in vitro studies on the effects of thermotherapy on pro-
static stromal cell contractility and viability. The results
demonstrate that at temperatures of at least 50°C, heat ap-
plication acts primarily by inducing necrosis of contractile
prostatic cells. At lower temperatures, however, the con-
tractility of the surviving cells remains unchanged. Our da-
ta indicate that thermal therapy of BPH is probably only
successful if temperatures in excess of 50°C are achieved
and maintained.
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